期刊
FUTURE MEDICINAL CHEMISTRY
卷 10, 期 20, 页码 2457-2469出版社
Newlands Press Ltd
DOI: 10.4155/fmc-2018-0099
关键词
anticancer; FGF19; FGFR4; inhibitors; oncogenic role; signaling transduction; treatment regimens
资金
- Augusta University
- Spanish Ministry of Education, Culture and Sports [FPU13/04173 EST 16/00783]
FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/beta-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据